Acceptability and Feasibility Study of Non-alcoholic Beverages

July 17, 2026 updated by: Molly Anne Bowdring, Stanford University

Non-alcoholic Beverages as a Therapeutic Adjunct in Alcohol Use Disorder Treatment: a Pilot Study of Acceptability and Feasibility

This project will elucidate the acceptability and feasibility of incorporating provision of non-alcoholic beers into alcohol use disorder treatment, for patients interested in using non-alcoholic beers as part of their recovery from alcohol use disorder.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Enrolling by invitation

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Stanford, California, United States, 94304
        • Stanford Prevention Research Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Participants will be eligible if they report on the screening survey:

  • living in California and provide a California mailing address (to ship study materials to)
  • consuming ≤42 alcoholic beverages per week (as we seek to provide an equal count of the substitute beverage and budgetary restrictions prevent an amount greater than that)
  • having alcohol use disorder documented with ≥2 symptoms on the Alcohol Symptom Checklist
  • being enrolled in Ria Health treatment
  • having English language fluency

Exclusion Criteria:

  • Individuals will be excluded at the online screener survey stage if they do not meet all of the inclusion criteria.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Non-alcoholic beer
Participants will receive non-alcoholic beers (volume matching alcohol volume intake prior to alcohol use disorder treatment enrollment) for 6 weeks.
Other: Non-alcoholic beer
Participants will receive non-alcoholic beers and will be encouraged to consume the beverages to the extent they find useful/desirable during the 6-week study period.
Other: Sparkling water
Participants will receive sparkling water (volume matching alcohol volume intake prior to alcohol use disorder treatment enrollment) for 6 weeks.
Other: Sparkling water
Participants will receive sparkling water and will be encouraged to consume the beverages to the extent they find useful/desirable during the 6-week study period.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Participant Beverage Satisfaction (Acceptability)
Time Frame: Assessed at the end of week 6
"How satisfied were you with the beverages you received in this study?" with 5-pt scale response options ranging from "Very Unsatisfied" to "Very Satisfied." Higher scores [split by condition] will indicate greater acceptability.
Assessed at the end of week 6
Participant Intention to Consume Assigned Beverage in the Future (Acceptability)
Time Frame: Assessed at the end of week 6
"Do you intend to consume the beverage type you received in the future?" with 5-pt scale response options ranging from "Definitely not" to "Definitely." Higher scores [split by condition] will indicate greater acceptability.
Assessed at the end of week 6
Participant Likelihood of Recommending Beverage (Acceptability)
Time Frame: Assessed at the end of week 6
"Would you recommend the use of the beverage type you received for people who have alcohol use disorder?" with 5-pt scale response options ranging from "Definitely not" to "Definitely." Higher scores [split by condition] will indicate greater acceptability.
Assessed at the end of week 6
Screened Out of Contacted (Feasibility)
Time Frame: Beginning of recruitment to end of recruitment (approximately 3-6 months)
Percentage of participants who completed the screening measure out of those who were contacted. Higher percentage will indicate greater feasibility.
Beginning of recruitment to end of recruitment (approximately 3-6 months)
Eligible Out of Screened (Feasibility)
Time Frame: Beginning of recruitment to end of recruitment (approximately 3-6 months)
Percentage of participants who screen eligible out of those who were screened. Higher percentage will indicate greater feasibility.
Beginning of recruitment to end of recruitment (approximately 3-6 months)
Enrolled Out of Eligible (Feasibility)
Time Frame: Beginning of recruitment to end of recruitment (approximately 3-6 months)
Percentage of participants who enrolled out of those who screened eligible. Higher percentage will indicate greater feasibility.
Beginning of recruitment to end of recruitment (approximately 3-6 months)
Retention (Feasibility)
Time Frame: Beginning of recruitment to end of data collection (approximately 3-6 months)
Percentage of participants who completed the study out of those who enrolled. Higher percentage [split by condition] will indicate greater feasibility.
Beginning of recruitment to end of data collection (approximately 3-6 months)
Perception of Beverage Supply (Feasibility)
Time Frame: Assessed at the end of week 6
Percentage of participants whose response to "How was the supply of beverages you received throughout the study?" is "just right" [as opposed to "too little" or "too much"]. Higher percentage [split by condition] will indicate greater feasibility.
Assessed at the end of week 6

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Average Blood Alcohol Content Across 6 Weeks
Time Frame: Study weeks 1-6
Average blood alcohol content (measured via breathalyzer) across the 6-week period split by condition.
Study weeks 1-6
Change in Blood Alcohol Content Across 6 Weeks
Time Frame: Treatment entry to week 6
Slopes of blood alcohol content separated by condition for: a) start of treatment to pre-study and b) during the 6-week study period [split by condition].
Treatment entry to week 6
Average Number of Days with Breathalyzer Readings
Time Frame: Assessed at 6 weeks.
Average number of days with breathalyzer readings across the 6-week study.
Assessed at 6 weeks.
Median Number of Breathalyzer Readings Among Days with Readings
Time Frame: Assessed at 6 weeks.
Median number of breathalyzer readings among days with readings across the 6-week study.
Assessed at 6 weeks.
Change in Reported Alcohol Use
Time Frame: Baseline to 6 weeks.
Percentage of participants endorsing use of study-provided beverages who experienced (a) increase in alcohol use (defined as change in average use per week pre-study to average use per week across the study), (b) no change in alcohol use, (c) decrease in alcohol use [split by condition].
Baseline to 6 weeks.
Perceived Change in Craving
Time Frame: Assessed at 6 weeks.
Percentage of participants endorsing use of study-provided beverages who reported (a) increased in desire to drink alcohol, (b) no change in desire to drink alcohol, (c) decreased desire to drink alcohol [split by condition] in response to the item "When I drink the study provided beverages I experience…Less desire to drink alcohol; No change in my desire to drink alcohol; or More desire to drink alcohol.
Assessed at 6 weeks.
Perceived Change in Alcohol Use
Time Frame: Assessed at 6 weeks.
Percentage of participants endorsing use of study-provided beverages who reported (a) increased in alcohol use, (b) no change in alcohol use, (c) increased alcohol use [split by condition] in response to the item "Because I drink the study provided beverages I drink...Less alcohol than I otherwise would; The same amount of alcohol that I otherwise would; or More alcohol than I otherwise would."
Assessed at 6 weeks.
Perceived Impact of Beverages on Recovery
Time Frame: Assessed at 6 weeks.
Percentage of participants who responded to the item "What impact did the study provided beverages have on your recovery from alcohol use disorder?" with (a) Harmful; (b) No impact; or (c) Helpful [split by condition].
Assessed at 6 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Stanford University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Molly A Bowdring, PhD, Stanford University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 14, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 27, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 27, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 5, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 20, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 17, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 83997
  • 1K99AA031716 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data will be uploaded to the NIAAA data archive

IPD Sharing Time Frame

Analytic code, data, and data dictionary will be uploaded upon at the time of primary results submission to an academic journal.

IPD Sharing Supporting Information Type

  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings